Brief: Alk-Abello Says Phase 3 Clinical Trial Meets Primary Endpoint

Alk-Abello A/S

11/10/2023 15:16

Oct 11 (Reuters) - ALK-Abello A/S  ALKb.CO :
    * REG-LARGE PHASE 3 CLINICAL TRIAL SUCCESSFULLY MEETS
PRIMARY
ENDPOINT, CONFIRMING THE POTENTIAL OF ALK’S TREE TABLET IN
CHILDREN
    * RESULTS WERE HIGHLY STATISTICALLY SIGNIFICANT
    * TRIAL ALSO DEMONSTRATED IMPROVEMENT IN TCS DURING ENTIRE
TREE
POLLEN SEASON (KEY SECONDARY ENDPOINT)
    * TRIAL DEMONSTRATED THAT TREATMENT WITH TREE TABLET WAS
WELL
TOLERATED AND HAD A FAVOURABLE SAFETY PROFILE, SIMILAR TO SAFETY
PROFILE REPORTED IN OTHER TRIALS

Source text for Eikon:  ID:nGNE5KD8bW 
Further company coverage:  ALKb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))